[1] |
中国中西医结合学会皮肤性病专业委员会色素病学组. 白癜风诊疗共识(2018版)[J]. 中华皮肤科杂志, 2018,51(4):247⁃250. doi: 10.3760/cma.j.issn.0412⁃4030.2018.04.001.
|
[2] |
van Geel N, Passeron T, Wolkerstorfer A, et al. Reliability and validity of the Vitiligo Signs of Activity Score (VSAS)[J]. Br J Dermatol, 2020,183(5):883⁃890. doi: 10.1111/bjd.18950.
|
[3] |
Speeckaert R, Speeckaert M, De Schepper S, et al. Biomarkers of disease activity in vitiligo: a systematic review[J]. Autoimmun Rev, 2017,16(9):937⁃945. doi: 10.1016/j.autrev.2017.07.005.
|
[4] |
Xiang W, Xu A, Xu J, et al. In vivo confocal laser scanning microscopy of hypopigmented macules: a preliminary comparison of confocal images in vitiligo, nevus depigmentosus and postinflammatory hypopigmentation[J]. Lasers Med Sci, 2010,25(4):551⁃558. doi: 10.1007/s10103⁃010⁃0764⁃2.
|
[5] |
Bae JM, Oh SH, Kang HY, et al. Development and validation of the Vitiligo Extent Score for a Target Area (VESTA) to assess the treatment response of a target lesion[J]. Pigment Cell Melanoma Res, 2019,32(2):315⁃319. doi: 10.1111/pcmr.12730.
|
[6] |
Hamzavi I, Jain H, McLean D, et al. Parametric modeling of narrowband UV⁃B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index[J]. Arch Dermatol, 2004,140(6):677⁃683. doi: 10.1001/archderm.140.6. 677.
|
[7] |
van Geel N, Lommerts J, Bekkenk M, et al. Development and validation of the Vitiligo Extent Score (VES): an international collaborative initiative[J]. J Invest Dermatol, 2016,136(5):978⁃984. doi: 10.1016/j.jid.2015.12.040.
|
[8] |
Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference[J]. Pigment Cell Melanoma Res, 2012,25(3):E1⁃E13. doi: 10.1111/j.1755⁃148X.2012.00997.x.
|
[9] |
Rodrigues M, Ezzedine K, Hamzavi I, et al. Current and emerging treatments for vitiligo[J]. J Am Acad Dermatol, 2017,77(1):17⁃29. doi: 10.1016/j.jaad.2016.11.010.
|
[10] |
Kanwar AJ, Mahajan R, Parsad D. Low⁃dose oral mini⁃pulse dexamethasone therapy in progressive unstable vitiligo[J]. J Cutan Med Surg, 2013,17(4):259⁃268. doi: 10.2310/7750.2013. 12053.
|
[11] |
Lee J, Chu H, Lee H, et al. A retrospective study of methylprednisolone mini⁃pulse therapy combined with narrow⁃band UVB in non⁃segmental vitiligo[J]. Dermatology, 2016,232(2):224⁃229. doi: 10.1159/000439563.
|
[12] |
林洁, 樊奇敏, 许爱娥. 窄谱中波紫外线治疗白癜风平台期相关研究[J]. 临床皮肤科杂志, 2016,45(6):465⁃468.
|
[13] |
Khullar G, Kanwar AJ, Singh S, et al. Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB⁃UVB vs. NB⁃UVB alone in the treatment of vitiligo: a 24⁃week prospective right⁃left comparative clinical trial[J]. J Eur Acad Dermatol Venereol, 2015,29(5):925⁃932. doi: 10.1111/jdv.12726.
|
[14] |
Hu W, Xu Y, Ma Y, et al. Efficacy of the topical calcineurin inhibitors tacrolimus and pimecrolimus in the treatment of vitiligo in infants under 2 years of age: a randomized, open⁃label pilot study[J]. Clin Drug Investig, 2019,39(12):1233⁃1238. doi: 10.1007/s40261⁃019⁃00845⁃x.
|
[15] |
Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo[J]. Br J Dermatol, 2001,145(3):476⁃479. doi: 10.1046/j.1365⁃2133.2001.04381.x.
|
[16] |
de Menezes AF, Oliveira de Carvalho F, Barreto RS, et al. Pharmacologic treatment of vitiligo in children and adolescents: a systematic review[J]. Pediatr Dermatol, 2017,34(1):13⁃24. doi: 10.1111/pde.13024.
|
[17] |
Margolis DJ, Abuabara K, Hoffstad OJ, et al. Association between malignancy and topical use of pimecrolimus[J]. JAMA Dermatol, 2015,151(6):594⁃599. doi: 10.1001/jamadermatol. 2014.4305.
|
[18] |
Oiso N, Kawada A. Freckling promoted by topical tacalcitol in a Japanese boy with left eyelid vitiligo[J]. Pediatr Dermatol, 2012,29(5):671⁃672. doi: 10.1111/j.1525⁃1470.2011.01559.x.
|
[19] |
Passeron T. Medical and maintenance treatments for vitiligo[J]. Dermatol Clin, 2017,35(2):163⁃170. doi: 10.1016/j.det.2016. 11.007.
|
[20] |
Mohammad TF, Al⁃Jamal M, Hamzavi IH, et al. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo[J]. J Am Acad Dermatol, 2017,76(5):879⁃888. doi: 10.1016/j.jaad.2016.12.041.
|
[21] |
Rosmarin D , Pandya A G , Lebwohl M , et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial[J]. The Lancet, 2020,396(10244):110⁃120. doi:10.1016/S0140⁃6736(20)30609⁃7.
|